Strides Pharma Science quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	1,430	1,221	+17.1%
EBITDA	251	232	+8.4%
EBITDA margin	17.6%	19.0%	−1.4 pts
Profit before tax	150	154	−3.0%
Net profit	134	132	+2.0%
EPS	₹14.19	₹13.84	+2.5%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	1,430	1,265	1,323	1,195	1,221	1,120	1,190	1,154	1,201	1,088	1,084	1,038	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	4.1	4.9	8.1	107	27.1	8.6	12.0	5.6	28.4	12.7	−13.5	8.8
	1,434	1,270	1,332	1,302	1,248	1,128	1,202	1,159	1,230	1,100	1,070	1,046
	565	415	409	460	430	261	270	477	449	364	354	375
	181	166	127	71.4	41.8	121	232	134	55.3	79.4	113	50.7
	−116	−85.9	−0.1	−68.1	43.7	62.8	−2.4	−130	−6.3	−23.2	−50.3	−4.6
	238	243	247	230	227	226	223	216	219	212	199	184
	46.5	40.6	41.6	43.4	46.1	47.5	50.3	52.2	82.1	80.4	80.2	79.3
	57.2	56.4	53.2	50.6	49.6	48.9	48.9	48.4	50.5	48.6	49.8	51.2
	311	297	300	266	247	232	251	248	248	238	239	238
	1,283	1,133	1,179	1,053	1,085	998	1,072	1,044	1,098	1,000	984	974
	251	230	240	236	232	218	218	210	236	217	230	194
	194	173	186	185	182	169	169	162	185	168	180	143
Profit
	151	138	153	249	163	130	131	115	132	101	86.3	72.1
	−1.7	63.2	−6.4	−3.3	−8.8	−8.4	−27.4	−2.4	−3.9	−3.7	−8.1	−10.1
	150	201	147	246	154	122	103	113	128	97.0	78.2	62.0
	21.7	29.0	16.6	27.6	22.7	10.9	4.6	11.7	22.9	19.1	12.5	3.7
	−5.4	5.1	2.2	9.7	−1.1	5.6	16.2	12.1	−1.6	−2.3	6.8	6.4
	16.3	34.1	18.8	37.4	21.6	16.5	20.8	23.8	21.2	16.9	19.3	10.1
	0.9	−1.3	1.4	−0.0	−1.0	0.1	3.1	1.0	−12.8	−11.8	−48.6	−52.0
	134	165	129	208	132	106	85.6	90.0	93.7	68.3	10.4	54.1
	133	167	128	208	133	105	82.5	89.1	106	80.1	59.0	51.9
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	54.1
	39.2	28.9	19.7	9.9	−24.3	38.7	77.1	72.4	10.0	−9.9	−53.3	6.1
	173	194	149	218	107	144	163	162	104	58.5	−42.9	60.2
	131	157	127	202	128	99.6	82.2	87.9	93.2	70.2	18.2	49.7
	3.3	8.6	2.3	6.0	4.0	6.0	3.4	2.1	0.4	−1.9	−7.7	4.4
Per share
	₹14.19	₹17.02	₹13.77	₹21.93	₹13.84	₹10.81	₹8.92	₹9.56	₹10.14	₹7.64	₹1.98	₹5.43
	₹14.19	₹17.02	₹13.77	₹21.92	₹13.84	₹10.81	₹8.92	₹9.55	₹10.12	₹7.62	₹1.98	₹5.42
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	54.1
Other comprehensive income — detail
	39.2	28.9	19.7	9.9	−24.3	38.7	77.1	—	—	—	—	—
	−27.4	32.3	−57.5	−5.4	−65.8	82.0	79.0	106	−0.2	−0.4	−56.5	0.3
	−5.8	8.1	−11.8	−1.4	−16.6	20.6	19.2	—	—	—	—	—
	—	—	—	—	—	—	—	26.9	0.0	0.0	−1.9	−0.0
	64.5	12.6	60.6	12.4	14.5	−26.0	18.6	−11.5	13.3	−8.5	1.9	5.8
	3.8	7.8	−4.7	−1.5	−10.5	−3.3	1.3	—	—	—	—	—
	—	—	—	—	—	—	—	−4.5	3.0	0.9	0.6	0.0
	169	185	146	211	102	138	159	155	108	59.3	−37.3	59.6
	3.9	9.3	2.5	7.1	5.0	6.3	3.6	7.9	−3.8	−0.9	−5.5	0.6
Per share — as-filed variants
	₹14.19	₹17.02	₹13.77	₹21.93	₹13.84	₹10.81	₹8.92	₹9.56	₹10.14	₹7.64	₹1.97	−₹0.49
	₹14.19	₹17.02	₹13.77	₹21.92	₹13.84	₹10.81	₹8.92	₹9.55	₹10.12	₹7.62	₹1.97	−₹0.49
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.01	₹5.92
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.01	₹5.91
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	800	770	787	732	706	675	691	674	703	667	668	616
	56.0%	60.9%	59.5%	61.2%	57.8%	60.3%	58.1%	58.4%	58.5%	61.3%	61.6%	59.4%
Adjusted (ex-exceptional items) — derived
	151	138	153	249	163	130	131	115	132	101	86.3	72.1
	−1.7	63.2	−6.4	−3.3	−8.8	−8.4	−27.4	−2.4	−3.9	−3.7	−8.1	−10.1
	136	113	135	211	139	113	108	92.0	96.9	71.4	16.5	62.5
	₹14.35	₹11.62	₹14.36	₹22.22	₹14.63	₹11.55	₹11.20	₹9.76	₹10.49	₹7.99	₹3.13	₹6.28

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,097.50

Strides Pharma Science Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹10,116 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	1,037.7	1,084.0	1,087.5	1,201.1	1,153.7	1,190.4	1,119.7	1,220.8	1,194.6	1,323.5	1,265.4	1,429.7
Other Income	8.8	-13.5	12.7	28.4	5.6	12.0	8.6	27.1	106.9	8.1	4.9	4.1
Total Income	1,046.4	1,070.5	1,100.2	1,229.5	1,159.3	1,202.4	1,128.3	1,248.0	1,301.5	1,331.6	1,270.3	1,433.8
Expenses
+ Cost of Materials Consumed	375.1	353.8	364.2	448.9	476.6	269.7	260.6	429.8	459.7	408.9	414.7	564.9
+ Purchases of Stock-in-Trade	50.7	112.6	79.4	55.3	133.8	231.6	120.9	41.8	71.4	127.4	166.4	181.0
+ Changes in Inventories	-4.6	-50.3	-23.2	-6.3	-130.2	-2.4	62.8	43.7	-68.1	-0.1	-85.9	-116.5
+ Employee Benefit Expense	184.5	199.2	212.2	219.4	215.6	222.9	225.5	226.8	229.5	247.1	243.0	238.3
+ Finance Costs	79.3	80.2	80.4	82.1	52.2	50.3	47.5	46.1	43.4	41.6	40.6	46.5
+ Depreciation & Amortisation	51.2	49.8	48.6	50.5	48.4	48.9	48.9	49.6	50.6	53.2	56.4	57.2
+ Other Expenses	238.1	238.9	237.9	248.0	247.6	250.7	231.9	247.2	266.2	300.4	297.5	311.1
Total Expenses	974.4	984.2	999.5	1,098.0	1,044.0	1,071.7	998.0	1,085.0	1,052.7	1,178.6	1,132.6	1,282.6
EBITDA	193.8	229.7	217.0	235.8	210.3	217.9	218.1	231.6	235.9	239.7	229.8	250.9
EBIT	142.6	180.0	168.4	185.3	161.9	169.0	169.2	181.9	185.3	186.5	173.4	193.7
Profit
PBT before Exceptional Items	72.1	86.3	100.7	131.5	115.3	130.7	130.3	162.9	248.8	153.0	137.7	151.2
+ Exceptional Items	-10.1	-8.1	-3.7	-3.9	-2.4	-27.4	-8.4	-8.8	-3.3	-6.4	63.2	-1.7
Pretax Income	62.0	78.2	97.0	127.7	112.9	103.3	121.9	154.2	245.5	146.6	200.9	149.5
+ Current Tax	3.7	12.5	19.1	22.9	11.7	4.6	10.9	22.7	27.6	16.6	29.0	21.7
+ Deferred Tax	6.4	6.8	-2.3	-1.6	12.1	16.2	5.6	-1.1	9.7	2.2	5.1	-5.4
Tax Expense	10.1	19.3	16.9	21.2	23.8	20.8	16.5	21.6	37.4	18.8	34.1	16.3
+ Share of Associates & JVs	-52.0	-48.6	-11.8	-12.8	1.0	3.1	0.1	-1.0	-0.0	1.4	-1.3	0.9
Net Income	54.1	10.4	68.3	93.7	90.0	85.6	105.6	131.5	208.1	129.3	165.5	134.1
+ Net Income — Continuing Ops	51.9	59.0	80.1	106.5	89.1	82.5	105.5	132.6	208.2	127.8	166.8	133.2
+ Net Income — Discontinued Ops	54.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	6.1	-53.3	-9.9	10.0	72.4	77.1	38.7	-24.3	9.9	19.7	28.9	39.2
Total Comprehensive Income	60.2	-42.9	58.5	103.7	162.5	162.7	144.3	107.3	218.0	149.0	194.4	173.3
Net Income to Common	49.7	18.2	70.2	93.2	87.9	82.2	99.6	127.5	202.1	126.9	156.9	130.8
Minority Interest	4.4	-7.7	-1.9	0.4	2.1	3.4	6.0	4.0	6.0	2.3	8.6	3.3
Per Share
Basic EPS	5.43	1.98	7.64	10.14	9.56	8.92	10.81	13.84	21.93	13.77	17.02	14.19
Diluted EPS	5.42	1.98	7.62	10.12	9.55	8.92	10.81	13.84	21.92	13.77	17.02	14.19
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	54.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	77.1	38.7	-24.3	9.9	19.7	28.9	39.2
+ Items NOT to be Reclassified to P&L	0.3	-56.5	-0.4	-0.2	106.4	79.0	82.0	-65.8	-5.4	-57.5	32.3	-27.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	19.2	20.6	-16.6	-1.4	-11.8	8.1	-5.8
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-1.9	0.0	0.0	26.9	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	5.8	1.9	-8.5	13.3	-11.5	18.6	-26.0	14.5	12.4	60.6	12.6	64.5
+ Tax on Items to be Reclassified	—	—	—	—	—	1.3	-3.3	-10.5	-1.5	-4.7	7.8	3.8
+ Tax on Items to be Reclassified — alt tag	0.0	0.6	0.9	3.0	-4.5	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	59.6	-37.3	59.3	107.5	154.6	159.1	138.0	102.3	210.9	146.5	185.1	169.4
Comprehensive Income — Non-controlling Interests	0.6	-5.5	-0.9	-3.8	7.9	3.6	6.3	5.0	7.1	2.5	9.3	3.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	-0.49	1.97	7.64	10.14	9.56	8.92	10.81	13.84	21.93	13.77	17.02	14.19
Diluted EPS — Continuing Operations	-0.49	1.97	7.62	10.12	9.55	8.92	10.81	13.84	21.92	13.77	17.02	14.19
Basic EPS — Discontinued Operations	5.92	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	5.91	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	616.4	667.8	667.1	703.2	673.5	691.4	675.5	705.6	731.7	787.2	770.2	800.3
Gross Margin %	59.40	61.60	61.34	58.54	58.38	58.08	60.32	57.79	61.25	59.48	60.87	55.98
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	72.1	86.3	100.7	131.5	115.3	130.7	130.3	162.9	248.8	153.0	137.7	151.2
− Exceptional Items (reconciliation)	-10.1	-8.1	-3.7	-3.9	-2.4	-27.4	-8.4	-8.8	-3.3	-6.4	63.2	-1.7
Net Income Adj (tax-effected)	62.5	16.5	71.4	96.9	92.0	107.5	112.8	139.1	210.9	134.9	113.0	135.6
EPS Adj	6.28	3.13	7.99	10.49	9.76	11.20	11.55	14.63	22.22	14.36	11.62	14.35
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	91.9	91.9	91.9	92.0	92.2	92.2	92.2	92.2	92.2	92.2	92.2	92.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Strides Pharma Science Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 6:43 pm IST

Strides Pharma Science (NSE: STAR) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 6:43 pm IST. Consolidated net profit attributable to shareholders was ₹131 crore, up 2.6% from ₹128 crore in Q2 FY26 and down 16.6% from ₹157 crore in Q1 FY27. Revenue from operations was ₹1,430 crore, up 17.1% year on year and up 13.0% from the previous quarter.

Q2 FY26 results (a year earlier): 31 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹131 Cr+2.6% vs Q2 FY26−16.6% vs Q1 FY27Total incl. minority interest ₹134 Cr
Revenue from operations: ₹1,430 Cr+17.1% vs Q2 FY26+13.0% vs Q1 FY27
Operating margin (EBIT): 13.5%−1.4 pts vs Q2 FY26−0.2 pts vs Q1 FY27EBIT ₹194 Cr
EBITDA: ₹251 Cr+8.4% vs Q2 FY26+9.2% vs Q1 FY27margin 17.5%
Earnings per share (basic): ₹14.19+2.5% vs Q2 FY26−16.6% vs Q1 FY27
Net profit margin: 9.2%−1.3 pts vs Q2 FY26−3.2 pts vs Q1 FY27

Questions

What was Strides Pharma Science's net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹131 crore, up 2.6% from ₹128 crore in Q2 FY26 and down 16.6% from ₹157 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹134 crore.

What was Strides Pharma Science's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹194 crore, a margin of 13.5%, against 13.7% in Q1 FY27 and 14.9% in Q2 FY26. EBITDA was ₹251 crore, 17.5% of revenue.

What was Strides Pharma Science's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹556 crore in FY26 (April 2025–March 2026), down 84.5% from ₹3,593 crore in FY25. It was a loss of ₹70.6 crore in FY24 and a loss of ₹203 crore in FY23.

What was Strides Pharma Science's revenue in Q2 FY27?

Revenue from operations was ₹1,430 crore, up 17.1% year on year and up 13.0% from the previous quarter.

What was Strides Pharma Science's EPS in Q2 FY27?

Basic earnings per share were ₹14.19, against ₹13.84 in Q2 FY26.

When did Strides Pharma Science announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 6:43 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 31 October 2025.

How were Strides Pharma Science's Q2 FY27 results?

Both grew from a year earlier: net profit was up 2.6% at ₹131 crore and revenue was up 17.1% at ₹1,430 crore. The operating margin was 13.5%, down 1.4 percentage points from 14.9% a year earlier. Against Q1 FY27, net profit was down 16.6% and revenue up 13.0%.

What was Strides Pharma Science's net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹288 crore, up 26.7% from ₹227 crore in the same months a year earlier. Revenue from operations was ₹2,695 crore, up 15.1%.

What is Strides Pharma Science's net profit margin?

Strides Pharma Science's net profit margin was 9.2% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 10.4% in Q2 FY26 (down 1.3 percentage points). For FY26 as a whole it was 11.4%.

How has Strides Pharma Science's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹202 crore in Q3 FY26, ₹127 crore in Q4 FY26, ₹157 crore in Q1 FY27 and ₹131 crore in Q2 FY27. That is ₹617 crore over the four quarters, up 55.3% from ₹397 crore in the four quarters before. Revenue from operations: ₹1,195 crore, ₹1,323 crore, ₹1,265 crore and ₹1,430 crore.

What was Strides Pharma Science's revenue in FY26?

Revenue from operations was ₹4,859 crore in FY26 (April 2025–March 2026), up 6.4% from ₹4,565 crore in FY25. It was ₹4,051 crore in FY24 and ₹3,688 crore in FY23: up 31.7% over three years, 9.6% a year on average.

When will Strides Pharma Science announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Strides Pharma Science figures come from?

From Strides Pharma Science's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.